IMDX

Insight Molecular DiagnosticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

Peers tracked

U.S. public peers

Grade Position

Below peers

vs peer average

IMDX vs peer average

27/100

IMDX vs. peer average (F vs. D)

Grade spread

A 1 · B 2 · C 2 · D 2 · F 4

Graded peers loaded

Coverage

11 graded

100% of tracked

Peer overview

PRQR is the first available peer comparator.

Clinical-stage small-cap biotech with event-driven valuation swings; useful as a loose comparator for regulatory milestone sensitivity rather than business-model similarity.

✓Peer source comes from the stored AI memo or peer model

✓Grades and factor rows use RankAlpha API data when available

✓Missing peer scores remain blank instead of being estimated

✓Side-by-side comparison keeps the data contract visible

Top peerPRQRProQR Therapeutics

IMDX

Insight Molecular Diagnostics

PRQR

ProQR Therapeutics

Grade

Momentum

Value

Sentiment

Setup Bias

Net —

Market Cap

Posture

Defensive

Open Side-by-Side Comparison Compare all

Grade position vs PRQR

IMDX / PRQR

Grade Position

Below peers

IMDX vs. peer average (F vs. D)

27/100

Momentum

PRQR

Value

IMDX

Sentiment

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank

Ticker

Company

Grade

Grade score

vs IMDX

PRQR

20/100

Even

OVID

80/100

-3

CABA

40/100

-1

ADCT

ADC Therapeutics Ltd Common

60/100

-2

LENZ

LENZ Therapeutics Inc Common

80/100

-3

PRQR is the first peer returned for this comparison set.